Recombinant Human Endothelial-Monocyte Activating Polypeptide II
Key features and details
- Species:
- Abbreviation:
- Source:
- Molecular Weight:
- Purity:
- Endotoxin:
- Accession #:
- Storage:
-
Brand:
CAT.NO. : ARP6726
RMB Please choose
RMB Please choose
Size:
Trail, Bulk size or Custom requests Please contact us
*产品价格可能会有所调整，请以品牌方官网实时更新的价格为准，以确保准确性。
Product Details
Background
Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid. Recombinant Human EMAP-II is an 18.3kDa globular protein containing 166 amino acid.
New Products
